Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > AVTX Avalo Therapeutics > Company Profile
AVTX Avalo Therapeutics
5.460
+0.140+2.63%
Symbol
AVTX
Company Name
Avalo Therapeutics
Listing Date
11/13/2015
Establishment Date
2011
CEO
Dr. Garry A. Neil, M.D.
Market
NASDAQ
Employees
44
Securities Type
DR
Fiscal Year Ends
12-31
Address
540 Gaither Road,Suite 400
City
Rockville
Province
Maryland
Country
United States of America
Zip code
20850
Phone
1-410-522-8707
Profile
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Company Overview
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
CEO: Dr. Garry A. Neil, M.D.
Market: NASDAQ
Listing Date: 11/13/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist